
## SHOULD YOU CONSIDER MULTI-CANCER EARLY DETECTION (MCED) SCREENING?

## **ONLY 25% OF CANCERS** ARE DETECTED BY A PREVENTIVE SCREENING TEST



The addition of MCED testing to routine cancer screening could result in 3x as many cancers diagnosed as routine screening alone, with at least 17% fewer cancer deaths per year.

## **2023 USPSTF RECOMMENDATIONS FOR SCREENING ASYMPTOMATIC PATIENTS**

CANCER	SCREENING	CRITERIA	YEAR PUBLISHED
BREAST	Biennial screening mammography	Women aged 40-74 years	Draft Recommendation Statement (May 2023)
CERVICAL	<ul> <li>Cervical cytology every 3 years</li> </ul>	Women aged 21-29 years	2018; update in progress
	<ul> <li>Cervical cytology every 3 years <i>OR</i></li> <li>High-risk human papillomavirus (hrHPV) every 5 years <i>OR</i></li> <li>hrHPV + cervical cytology every 5 years</li> </ul>	Women aged 30-65 years	
COLORECTAL	<ul> <li>Stool-based testing</li> <li>Annual fecal immunochemical test (FIT) or high-sensitivity guaiac-based testing</li> <li>sDNA-FIT (stool DNA test with FIT) every 1 to 3 years</li> <li>Colonoscopy every 10 years</li> <li>Computed tomography colonography every 5 years</li> <li>Flexible sigmoidoscopy</li> <li>Every 5 years</li> <li>Every 10 years + annual FIT</li> </ul>	<ul> <li>Age 45-75 years</li> <li>Certain populations aged 76-85 years</li> </ul>	2021
LUNG	Annual low-dose computed tomography (LDCT)	Age 50-80 years and ≥20 pack per year history of smoking and currently smoke or quit within the past 15 years	2021
PROSTATE	Prostate-specific antigen (PSA) testing	Men aged 55-69 years when elected with shared decision-making	2018

## **ELIGIBILITY FOR MCED SCREENING**

#### ✓ WHO IS ELIGIBLE

Age ≥50 years Family or personal history of cancer History of childhood cancer Known genetic mutations

#### **RISK FACTORS**

• Alcohol

- Exposure to cancer-causing substances (eg, fire smoke, tobacco smoke, radiation, sunlight)
- Chronic inflammation

• Diet

- Hormones
- Immunosuppression
- Infectious agents (eg, viruses, parasites)
- Overweight/obesity
- Tobacco

## 🗙 WHO IS NOT ELIGIBLE

- Pediatric populations (<21 years)
- Pregnant patients
- Patients with active cancer diagnosis or treated for cancer in last 3 years

#### **PATIENT RESOURCES**

Overview of MCED: www.preventcancer.org/multi-cancer-early-detection/

Frequently asked questions about MCED: www.preventcancer.org/multi-cancer-early-detection/frequently-asked-questions/ Learn more about the currently available blood-based MCED test: www.galleri.com

## **HOW TO IMPLEMENT MCED SCREENING IN PRACTICE**

## **ASSESS PATIENT ELIGIBILITY BASED ON RISK FACTORS**

## **PRETEST COUNSELING**

- Educate patients about the MCED test and implications of possible results
- Order MCED test for interested patients
  - » Currently available MCED tests can be ordered through the manufacturer's website either by the clinician's office or directly by the patient. Patient schedules blood draw through participating laboratory.

## **MCED TEST PROCESSING**

- Patient blood sample sent to test manufacturer
- Results delivered via portal within 2 weeks of sample receipt by laboratory

## **PATIENT NOTIFICATION**

#### A. "No Cancer Signal Detected"

• Patient notified and additional health screenings discussed as needed

#### **B. "Cancer Signal Detected"**

 Diagnostic results and next steps discussed with patient

# CLINICAL CARE PATHWAYS FOLLOWING A "SIGNAL DETECTED" RESULT

### **CANCER SIGNAL ORIGIN PREDICTION**

## **PROPOSED FIRST-LINE PROCEDURES**

**MULTIPLE MYELOMA** 

#### Blood workup including peripheral blood smear, CBC with differential; chemistry tests including creatinine clearance, protein electrophoresis of blood/urine

**UPPER GI (ESOPHAGUS, STOMACH)** 

**COLORECTAL** 

**HEAD AND NECK** 


**PANCREAS, GALLBLADDER** 

Endoscopy

Colonoscopy

Physical exam, fiber optic exam, ultrasound

CT abdomen with IV contrast, MRCP, GI referral





Please visit www.ExchangeCME.com/MCEDJeopardyResources to access the references used in this handout and other clinician resources about MCEDs.

CBC, complete blood count; CT, computed tomography; GL agstrointestinal; IV, intravenous; MRL magnetic resonance imagina; MRCP, magnetic resonance cholangiopancreatography; PET-CT, positron emission tomography-computed tomography